BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

On Heels Of Record Third Quarter, Gentiae Clinical Research Recruits New CEO


10/19/2005 5:09:10 PM

SAN FRANCISCO, Aug. 24 /PRNewswire/ -- Gentiae Clinical Research, Inc. a provider of centralized cardiac safety monitoring & imaging services, announced today record revenue growth for the first three quarters of fiscal year 2005. In anticipation of the company's ongoing rapid growth, Gentiae announced the appointment of Craig Albright as its new chief executive officer.

"On behalf of Gentiae's board of directors, I'm very excited to welcome Craig to our team," said board member Mike Kaplan, of venture firm Three Arch Partners. "With his track record in health care, and his credibility in the financing community, Craig will provide Gentiae with the leadership it needs to expand on its current success." Added board member Bill Hinton, "We're at a pivotal time in the company's expansion, and Craig has the experience to build and lead the team at Gentiae to take advantage of an exceptional market opportunity."

"I'm delighted to join Gentiae as it transitions for the next stage of growth," said Albright, "and it is a privilege to build on the success of the company to date. FDA scrutiny and concern for cardiac safety is creating a tremendous market opportunity for ECG and other cardiovascular core lab services. The company's founding management team has built Gentiae into a true clinical brand that is recognized in the industry as the quality standard."

As CEO of Free & Clear, Inc., recipient of multiple industry awards for clinical excellence, Albright led the company through its spinout from parent Group Health Cooperative and through subsequent rounds of venture financing to become a commercial leader in the disease management and risk factor treatment market. Over the past 20 years, Albright has helped lead the rapid growth of several notable venture backed health care companies, including Vivra Specialty Partners, Inc. and Datis Corporation. Albright has also served as a retained advisor to several leading private equity groups, including Three Arch, Kohlberg & Company, and Warburg Pincus.

Gentiae spun off from its parent organization, the Ischemia Research and Education Foundation (IREF), in September of 2001. It has received funding from IREF and Three Arch Partners of Portola Valley, California.

In addition to appointing a new CEO, Gentiae has also announced that Jay B. Hunt has joined the Gentiae Board of Directors.

About Gentiae

Gentiae Clinical Research, Inc., based in the San Francisco Bay Area, is an internationally recognized provider of cardiovascular core laboratory services including electrocardiography (ECG), Holter, echocardiography (ECHO), angiography, and MUGA. As a spin-off from the Ischemia Research and Education Foundation, Gentiae's ECG central laboratory inherits more than 18 years of experience interpreting cardiac safety data for global studies. Gentiae conducts research worldwide and provides a range of clinical trial management services that include protocol design, trial management, project management, data management, site monitoring, biostatistical analysis, report writing, and regulatory support. Gentiae manages the collection, measurement, clinical interpretation, analysis, archiving and submission of digital ECG data and diagnostic images through its LifeSignals(TM) technology platform.

The name Gentiae, based on a Latin root, means "people of the world." More information about Gentiae can be found at www.gentiae.com.

Gentiae Clinical Research, Inc.

CONTACT: Kristin Tedesco of Gentiae Clinical Research, Inc.,1-866-GENTIAE, or info@gentiae.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES